Compare Stocks

→ The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGN Apexigen	$0.39	$0.39	$0.33 ▼ $8.28	$9.57M	3.6	967,731 shs	N/A
CING Cingulate	$0.87 -1.1%	$1.08	$0.75 ▼ $23.80	$4.40M	-0.95	113,688 shs	18,528 shs
LMNL Liminal BioSciences	$8.50 +0.1%	$8.47	$3.10 ▼ $8.50	$26.35M	1.03	63,470 shs	5,000 shs
VBLT Vascular Biogenics	$5.46 -8.8%	$0.40	$0.10 ▼ $6.74	$423.91M	0.77	2.19 million shs	161,505 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGN Apexigen	0.00%	0.00%	0.00%	0.00%	-15.38%
CING Cingulate	-0.99%	-0.46%	-21.62%	-77.92%	-95.99%
LMNL Liminal BioSciences	0.00%	0.00%	0.00%	0.00%	+24.63%
VBLT Vascular Biogenics	0.00%	0.00%	0.00%	0.00%	+3,207.09%

The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGN Apexigen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CING Cingulate	2.5128 of 5 stars	3.2	4.0	0.0	0.0	1.7	4.2	0.0
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGN Apexigen	N/A	N/A	N/A	N/A
CING Cingulate	2.33	Hold	$8.00	819.54% Upside
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGN Apexigen	N/A	N/A	N/A	N/A	($0.09) per share	N/A
CING Cingulate	N/A	N/A	N/A	N/A	($5.88) per share	N/A
LMNL Liminal BioSciences	$310K	85.00	N/A	N/A	$8.97 per share	0.95
VBLT Vascular Biogenics	$660K	642.29	N/A	N/A	$0.32 per share	17.06

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGN Apexigen	-$32.07M	N/A	0.00	∞	N/A	N/A	-614.82%	-133.30%	N/A
CING Cingulate	-$23.53M	-$32.60	N/A	∞	N/A	N/A	N/A	-432.81%	5/8/2024 (Estimated)
LMNL Liminal BioSciences	$380K	$0.29	29.31	∞	N/A	248.35%	-88.44%	-64.15%	N/A
VBLT Vascular Biogenics	-$32.30M	-$0.21	N/A	∞	N/A	N/A	-73.45%	-54.11%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGN Apexigen	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGN Apexigen	N/A	0.82	0.82
CING Cingulate	N/A	0.06	0.06
LMNL Liminal BioSciences	0.02	2.78	2.78
VBLT Vascular Biogenics	N/A	4.63	4.63

Ownership

Institutional Ownership

Company	Institutional Ownership
APGN Apexigen	13.65%
CING Cingulate	41.31%
LMNL Liminal BioSciences	0.66%
VBLT Vascular Biogenics	0.96%

Insider Ownership

Company	Insider Ownership
APGN Apexigen	19.20%
CING Cingulate	38.43%
LMNL Liminal BioSciences	2.20%
VBLT Vascular Biogenics	6.13%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APGN Apexigen	11	24.86 million	20.09 million	Not Optionable
CING Cingulate	15	5.01 million	3.09 million	Not Optionable
LMNL Liminal BioSciences	251	3.10 million	3.04 million	Not Optionable
VBLT Vascular Biogenics	7	77.64 million	72.88 million	Optionable

CING, APGN, VBLT, and LMNL Headlines

Source	Headline
	Tommy Garten elected to VBL Hall of Fame therecorderonline.com - March 28 at 1:31 PM
	Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system nature.com - February 21 at 3:29 PM
	Vascular News and Research news-medical.net - November 25 at 2:28 PM
	Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26 msn.com - November 3 at 12:39 AM
	Notable Labs Closes Merger Transaction With VBL Therapeutics finance.yahoo.com - October 16 at 3:55 PM
	VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting finance.yahoo.com - October 12 at 3:13 PM
	VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting finance.yahoo.com - October 4 at 8:40 AM
	Vascular Biogenics Rises on Presentation Hype finance.yahoo.com - September 9 at 12:00 PM
	VBLT Stock Sees Decline of Approximately -0.22% in Last Five Days knoxdaily.com - September 7 at 9:15 PM
	VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC finance.yahoo.com - September 6 at 7:30 PM
	VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT businesswire.com - August 28 at 7:00 PM
	VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT businesswire.com - August 28 at 3:04 PM
	VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - August 14 at 8:09 AM
	Monitoring Vascular Biogenics Ltd. (VBLT) after recent insider movements knoxdaily.com - July 26 at 4:10 PM
	Vascular Biogenics (NASDAQ: VBLT) fool.com - July 23 at 5:52 PM
	Recent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT) knoxdaily.com - July 12 at 4:20 PM
	VBLT Stock Sees Decline of Approximately -4.31% in Last Five Days knoxdaily.com - July 7 at 2:11 PM
	Days-to-cover ratio for VBLT surges to 0.84 due to rise in short interest knoxdaily.com - June 23 at 8:26 PM
	The Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgery medscape.com - May 18 at 1:35 AM
	VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 15 at 8:03 PM
	Developing a Patient-Centered Approach to Vascular Access Device Selection medscape.com - May 10 at 8:52 AM
	CADASIL: The Most Common Hereditary Subcortical Vascular Dementia medscape.com - May 5 at 1:05 AM
	Aspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Disease medscape.com - May 2 at 8:00 PM
	Vascular Biogenics Stock (NASDAQ:VBLT), Dividends benzinga.com - April 4 at 1:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

5 Dividend Kings Stocks to Load Up on Now
March 27, 2024 7:45 AM
View 5 Dividend Kings Stocks to Load Up on Now
Buy the Dip in Paychex, Inc. for a Pay Check at Retirement
April 2, 2024 11:07 AM
View Buy the Dip in Paychex, Inc. for a Pay Check at Retirement
Heat Alert: Micron Just Got Named A Must-Own Stock for Q2
April 10, 2024 10:42 AM
View Heat Alert: Micron Just Got Named A Must-Own Stock for Q2
3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1
April 9, 2024 7:44 AM
View 3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1
Abbott Laboratories Outlook is Healthy: Buy the Dip
April 17, 2024 10:41 AM
View Abbott Laboratories Outlook is Healthy: Buy the Dip

All Headlines

Company Descriptions

Apexigen

NASDAQ:APGN

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

Cingulate

NASDAQ:CING

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Liminal BioSciences

NASDAQ:LMNL

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Vascular Biogenics

NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial